According to a study by Kraan et al, MYD88 mutations were relatively uncommon in activated B-cell-like (ABC) DLBCLs arising from the lymph nodes or intestine; however, the mutation rate was higher in tumors originating from immune-privileged sites.[40] Also, other studies have indicated that MYD88 mutations were more prevalent in lymphomas of the primary central nervous system.[34,41]. This evidence concerns the gene MYD88 and primary central nervous system lymphoma.